GO:0001698 gastrin-induced gastric acid secretion: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001698 describes the regulated release of gastric acid triggered when the hormone gastrin binds its receptor on target cells.
• The gastrin-ECL cell-parietal cell axis is the central functional circuit: gastrin stimulates enterochromaffin-like (ECL) cells to release histamine, which then drives parietal cell acid output.
• The cholecystokinin-B/gastrin receptor (CCKBR) is the receptor that mediates gastrin-induced acid secretion; its blockade or antisense knockdown attenuates the response.
• Gastrin-induced acid secretion is modulated by other hormones and neuropeptides, including ghrelin (synergistic), somatostatin (inhibitory), and cholecystokinin (negative regulator).
• Dysregulation of this process is linked to acid-related disorders such as gastroesophageal reflux disease, peptic ulcer disease, and gastrinomas, and to rebound acid hypersecretion after acid-suppressive therapy.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes in the gastrin-CCKBR-ECL-parietal cell pathway.
Description
Gastrin-induced gastric acid secretion (GO:0001698) is the regulated release of gastric acid that occurs when the peptide hormone gastrin interacts with its receptor on target cells. This biological process is a cornerstone of gastrointestinal physiology because it controls the acidity of the stomach lumen, which is required for protein digestion, micronutrient absorption, and defense against ingested pathogens. The process is not a simple linear event; it involves a coordinated axis in which gastrin acts on enterochromaffin-like (ECL) cells to release histamine, which in turn stimulates parietal cells to secrete hydrochloric acid. Understanding GO:0001698 is therefore essential for researchers studying gastric physiology, acid-related diseases, and the pharmacology of acid-suppressive drugs. The receptor mediating gastrin action, the cholecystokinin-B/gastrin receptor (CCKBR), is a key molecular node; blockade or antisense-mediated knockdown of this receptor attenuates gastrin-induced acid secretion in vivo. Moreover, the process is fine-tuned by multiple modulators, including ghrelin, somatostatin, and cholecystokinin, which can enhance or suppress the response depending on physiological context. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links, and experimental methods relevant to GO:0001698.
gastrin-induced gastric acid secretion At A Glance
| GO ID | GO:0001698 |
|---|---|
| GO term | gastrin-induced gastric acid secretion |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Regulated release of gastric acid in response to gastrin-receptor interaction |
| Key receptor | Cholecystokinin-B/gastrin receptor (CCKBR) |
| Key cell types | G cells (gastrin source), ECL cells (histamine release), parietal cells (acid secretion) |
| Major modulators | Ghrelin (synergistic), somatostatin (inhibitory), cholecystokinin (negative regulator) |
| Disease relevance | Peptic ulcer disease, gastroesophageal reflux disease, gastrinoma, rebound acid hypersecretion |
What Is GO:0001698?
In our own words, GO:0001698 (gastrin-induced gastric acid secretion) is the biological process in which the hormone gastrin binds to its receptor and triggers the regulated release of gastric acid from specialized stomach cells. The QuickGO definition states: "The regulated release of gastric acid induced by the interaction of gastrin with its receptor." This process is a stimulus-response pathway: gastrin, secreted by G cells in the antrum, acts on CCKBR on ECL cells and parietal cells, leading to histamine release and proton pump activation, ultimately acidifying the gastric lumen.
Why Is gastrin-induced gastric acid secretion Important in Cell Biology?
GO:0001698 is important because it defines the principal hormonal control of gastric acidity, a process that directly impacts digestion, nutrient absorption, and protection against pathogens. Dysregulation of this pathway contributes to common and clinically significant disorders, including peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome (gastrinoma). Pharmacological inhibition of gastric acid secretion, a mainstay of therapy for acid-related diseases, can lead to tolerance and rebound hypersecretion, highlighting the need to understand the underlying gastrin-driven mechanisms. Furthermore, the interplay between gastrin and other hormones such as ghrelin, somatostatin, and cholecystokinin reveals a complex regulatory network that is essential for maintaining gastric homeostasis. Researchers studying GO:0001698 can identify novel therapeutic targets and biomarkers for acid-related pathologies by dissecting the genes and signaling events that mediate this process.
• Controls gastric acid secretion, essential for protein digestion and absorption of iron, calcium, and vitamin B12.
• Central to the pathophysiology of peptic ulcer disease and gastroesophageal reflux disease.
• Mediates the action of gastrin, a hormone that also has trophic effects on the gastric mucosa.
• Involved in rebound acid hypersecretion after withdrawal of proton pump inhibitors.
• Provides a model for studying G-protein-coupled receptor signaling via CCKBR.
• Interacts with appetite-regulating hormones such as ghrelin, linking acid secretion to energy balance.
• Is modulated by somatostatin, a universal inhibitory peptide, offering targets for therapy.
• Cholecystokinin acts as a negative regulator, illustrating feedback control of acid secretion.
• Relevant to gastrinoma (Zollinger-Ellison syndrome), a tumor-driven acid hypersecretion state.
• Serves as a testbed for CRISPR-based functional genomics of hormone-receptor pathways.
What Happens During gastrin-induced gastric acid secretion?
Gastrin release and receptor binding
In simple terms: Gastrin is released into the blood and binds to its receptor on target cells in the stomach.
Gastrin is secreted by G cells in the gastric antrum in response to food intake. It travels through the bloodstream to reach enterochromaffin-like (ECL) cells and parietal cells, where it binds to the cholecystokinin-B/gastrin receptor (CCKBR). This interaction is the initiating event of GO:0001698. Blockade of CCKBR with specific antagonists reduces gastric acid secretion in conscious rats, confirming the receptor's essential role. Antisense oligonucleotides targeting CCKBR also attenuate gastrin-induced acid secretion, further validating the receptor as the primary mediator.
ECL cell activation and histamine release
In simple terms: Gastrin tells ECL cells to release histamine, which then acts on parietal cells.
Upon gastrin binding, ECL cells are stimulated to synthesize and release histamine. Histamine then acts on H2 receptors on parietal cells to trigger acid secretion. Somatostatin inhibits gastrin-induced histamine secretion and synthesis in the rat, providing a brake on this step. This ECL cell-parietal cell axis is a central amplification mechanism in gastrin-induced acid secretion.
Parietal cell activation and acid secretion
In simple terms: Parietal cells pump acid into the stomach lumen when stimulated by histamine and gastrin.
Parietal cells respond to histamine and direct gastrin stimulation by activating the H+/K+-ATPase (proton pump) on their secretory canaliculi, leading to hydrochloric acid secretion into the gastric lumen. This step is the final common pathway of GO:0001698. The process is regulated by multiple inputs, including cholecystokinin, which acts as a negative regulator of gastric acid secretion in humans.
Modulation by ghrelin and other hormones
In simple terms: Other hormones like ghrelin can boost or dampen the acid response.
Ghrelin acts synergistically with gastrin to enhance gastric acid secretion in rats, demonstrating that the process is not driven by gastrin alone. Somatostatin analogues such as octreotide can inhibit pentagastrin-induced gastric acid secretion when injected into the third cerebral ventricle, indicating central nervous system modulation. Cholecystokinin is a negative regulator of postprandial gastrin release and acid secretion in humans. These modulators fine-tune the intensity and duration of the acid response.
Feedback inhibition and termination
In simple terms: When acid levels are high enough, the stomach signals to stop further acid production.
As gastric pH drops, negative feedback mechanisms reduce gastrin release and acid secretion. Somatostatin, released from D cells in response to low pH, inhibits gastrin and histamine release, thereby limiting acid output. Cholecystokinin also contributes to negative regulation. This feedback ensures that gastric acid secretion is tightly controlled and prevents excessive acidification that could damage the mucosa.
Key Genes Involved in GO:0001698 gastrin-induced gastric acid secretion
The following genes and proteins are central to the gastrin-induced gastric acid secretion pathway, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAST | Encodes gastrin, the hormone that initiates the process | Target for knockout to abolish gastrin-induced acid secretion |
| CCKBR | Encodes the cholecystokinin-B/gastrin receptor that binds gastrin | Knockdown or knockout attenuates acid secretion; drug target |
| HRH2 | Encodes histamine H2 receptor on parietal cells | Mediates histamine-driven acid secretion; target of H2 blockers |
| ATP4A | Encodes the alpha subunit of H+/K+-ATPase proton pump | Final effector of acid secretion; target of proton pump inhibitors |
| ATP4B | Encodes the beta subunit of H+/K+-ATPase | Required for pump function; potential knockout model |
| SST | Encodes somatostatin, an inhibitor of gastrin and histamine release | Modulates acid secretion; knockout may cause hypersecretion |
| GHRL | Encodes ghrelin, which synergizes with gastrin | Enhances acid secretion; knockout may reduce response |
| CCK | Encodes cholecystokinin, a negative regulator | Modulates postprandial acid secretion; knockout may alter feedback |
| SLC18A2 | Encodes vesicular monoamine transporter 2 for histamine storage in ECL cells | Required for histamine release; potential target |
| HDC | Encodes histidine decarboxylase, the enzyme synthesizing histamine | Key for ECL cell histamine production; knockout reduces acid secretion |
| CHRM3 | Encodes M3 muscarinic receptor on parietal cells | Mediates vagal stimulation of acid secretion; synergistic with gastrin |
| SLC26A9 | Encodes a chloride channel in parietal cells | Facilitates acid secretion; potential modifier |
| KCNQ1 | Encodes a potassium channel in parietal cells | Supports proton pump function; knockout may impair acid secretion |
| GAST | Gastrin gene; alternative transcripts may affect activity | Splice variants may influence acid secretion levels |
| CCKBR | Receptor variants may alter ligand binding | Pharmacogenomics of acid suppression |
| SST | Somatostatin gene; regulates multiple steps | Therapeutic potential of somatostatin analogues |
| GHRL | Ghrelin gene; links to appetite and acid secretion | Dual role in energy balance and acid output |
How Is gastrin-induced gastric acid secretion Regulated?
The gastrin-induced gastric acid secretion process is regulated at multiple levels. Somatostatin acts as a potent inhibitor of gastrin-induced histamine secretion and synthesis in the rat, thereby dampening the acid response. Somatostatin analogues such as octreotide can inhibit pentagastrin-induced gastric acid secretion when administered centrally, indicating neuroendocrine control. Cholecystokinin is a negative regulator of gastric acid secretion and postprandial gastrin release in humans, providing a feedback loop. In contrast, ghrelin acts synergistically with gastrin to enhance acid secretion in rats. Additionally, pharmacological inhibition of acid secretion can lead to tolerance and rebound hypersecretion, reflecting adaptive changes in the regulatory network. These regulatory inputs ensure that gastric acid output is matched to physiological demand and that excessive acidification is prevented.
gastrin-induced gastric acid secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCKBR | Peptic ulcer disease, gastrinoma | Knockout mouse or point-mutation to abolish ligand binding |
| GAST | Zollinger-Ellison syndrome (gastrinoma) | Overexpression of gastrin in transgenic models |
| SST | Acid hypersecretion due to loss of inhibition | Somatostatin knockout mouse |
| GHRL | Metabolic syndrome with altered acid secretion | Ghrelin knockout or overexpression |
| CCK | Postprandial acid dysregulation | Cholecystokinin knockout mouse |
Peptic Ulcer Disease and Gastroesophageal Reflux Disease
Dysregulated gastrin-induced gastric acid secretion contributes to peptic ulcer disease and gastroesophageal reflux disease. Excessive acid production can damage the gastric and esophageal mucosa, leading to ulceration and inflammation. Pharmacological inhibition of acid secretion is a mainstay of therapy, but tolerance and rebound hypersecretion can occur upon withdrawal, underscoring the importance of understanding the underlying gastrin-driven mechanisms.
Gastrinoma and Zollinger-Ellison Syndrome
Gastrinomas are neuroendocrine tumors that secrete excessive gastrin, leading to massive gastric acid hypersecretion and severe peptic ulcer disease (Zollinger-Ellison syndrome). The pathophysiology directly involves uncontrolled activation of GO:0001698. Targeting the gastrin/CCKBR axis is a rational therapeutic approach, and receptor antagonists have been shown to reduce acid secretion in preclinical models.
Rebound Acid Hypersecretion
Prolonged use of proton pump inhibitors or other acid-suppressive drugs can lead to rebound acid hypersecretion upon discontinuation, a condition linked to the gastrin-ECL cell-parietal cell axis. This phenomenon highlights the plasticity of the regulatory mechanisms governing GO:0001698 and the need for careful clinical management.
Role of Hormonal Modulators in Disease
Alterations in ghrelin, somatostatin, or cholecystokinin signaling can modulate the severity of acid-related disorders. For example, somatostatin analogues are used to inhibit acid secretion in conditions like gastrinoma. Cholecystokinin's negative regulatory role suggests that its dysfunction could contribute to acid hypersecretion. Ghrelin's synergistic effect on acid secretion may link metabolic states to gastric pathology.
From gastrin-induced gastric acid secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CCKBR mediate gastrin-induced acid secretion? | CCKBR knockout mouse or CRISPR knockout cell line |
| What is the role of a specific CCKBR point mutation in receptor function? | Point-mutation knock-in mouse or cell line |
| Can we tag CCKBR to track its localization? | Knock-in of fluorescent or epitope tag at endogenous locus |
| Does overexpression of gastrin increase acid secretion? | Transgenic overexpression of GAST in mouse |
| Is somatostatin a negative regulator of acid secretion? | Somatostatin knockout or overexpression models |
| Does ghrelin synergize with gastrin in vivo? | Ghrelin knockout or overexpression models |
How to Study the gastrin-induced gastric acid secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Pylorus ligation in rats | Gastric acid output | In vivo validation of gastrin-induced secretion |
| Histamine assay | Histamine release from ECL cells | Assessing ECL cell activation |
| Radioligand binding | CCKBR receptor affinity | Characterizing receptor antagonists |
| Antisense knockdown | Reduction of CCKBR expression | Target validation in vivo |
| Plasma hormone RIA | Gastrin and CCK levels | Feedback regulation studies |
| Intracerebroventricular injection | Central modulation of acid secretion | Testing somatostatin analogues |
| Ghrelin co-administration | Synergistic effect on acid output | Hormonal interaction studies |
| Proton pump inhibitor withdrawal | Rebound acid hypersecretion | Clinical pharmacology studies |
In Vivo Acid Secretion Measurement
Gastric acid secretion can be measured in conscious rats or other animal models using pylorus ligation or perfusion techniques. For example, gastrin-induced acid secretion was attenuated by CCKBR antisense oligonucleotides in rats, demonstrating the utility of in vivo models. Ghrelin's synergistic effect on acid secretion was also demonstrated in rats. These methods are essential for validating the physiological relevance of genes identified in vitro.
Histamine and Hormone Assays
Histamine secretion and synthesis from ECL cells can be quantified using enzyme immunoassays or HPLC. Somatostatin inhibition of gastrin-induced histamine secretion was shown using such methods in rats. Gastrin and cholecystokinin levels in plasma can be measured by radioimmunoassay to assess feedback regulation.
Receptor Binding and Signaling Assays
CCKBR binding affinity and downstream signaling can be assessed using radioligand binding assays, cAMP measurements, or calcium imaging in transfected cell lines. Antisense oligonucleotides targeting CCKBR were used to reduce receptor expression and function in vitro and in vivo. These assays help dissect the molecular mechanism of gastrin action.
Genetic and Pharmacological Manipulation
Knockout mice, antisense oligonucleotides, and pharmacological antagonists are powerful tools to study GO:0001698. CCKBR blockade with antagonists reduced gastric acid secretion in conscious rats. Somatostatin analogue octreotide inhibited pentagastrin-induced acid secretion when injected centrally. These approaches allow causal testing of gene function.
How CRISPR Can Be Used to Study GO:0001698 gastrin-induced gastric acid secretion
Knockout
CRISPR knockout of CCKBR or GAST can abolish gastrin-induced gastric acid secretion, providing definitive evidence of their necessity. For example, antisense knockdown of CCKBR attenuated acid secretion in rats, and CRISPR knockout would offer a more complete and permanent loss-of-function model. Knockout of SST would be expected to enhance acid secretion due to loss of inhibition.
Point Mutation
Introducing point mutations in CCKBR that disrupt ligand binding or G-protein coupling can dissect the receptor's functional domains. Such models are valuable for understanding how specific residues contribute to gastrin-induced signaling. Point mutations in GAST could alter hormone processing or receptor affinity.
Knock-in
Knock-in of fluorescent or epitope tags at the endogenous CCKBR or GAST loci allows real-time tracking of receptor localization and hormone secretion. This approach can reveal dynamic changes during acid secretion. Knock-in of disease-associated variants can model human conditions.
Overexpression
Overexpression of GAST or CCKBR in transgenic models can lead to enhanced acid secretion and may model gastrinoma or acid hypersecretion states. Overexpression of GHRL could further amplify the response, as ghrelin synergizes with gastrin. These models are useful for testing therapeutic interventions.
How EDITGENE Supports gastrin-induced gastric acid secretion Research
Researchers studying gastrin-induced gastric acid secretion-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with the phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from knockout to precise point mutations and knock-in reporters.
Contact EDITGENE today to design your custom CRISPR model for gastrin-induced gastric acid secretion research.
Frequently Asked Questions About gastrin-induced gastric acid secretion
What is gastrin-induced gastric acid secretion?
Gastrin-induced gastric acid secretion (GO:0001698) is the regulated release of gastric acid triggered by the hormone gastrin binding to its receptor on target cells, primarily through the ECL cell-parietal cell axis.
What genes are involved in gastrin-induced gastric acid secretion?
Key genes include GAST (gastrin), CCKBR (gastrin receptor), HRH2 (histamine H2 receptor), ATP4A/ATP4B (proton pump subunits), SST (somatostatin), GHRL (ghrelin), and CCK (cholecystokinin).
How does gastrin stimulate acid secretion?
Gastrin binds to CCKBR on ECL cells, stimulating histamine release, which then acts on parietal cells to activate the proton pump and secrete acid. Direct effects on parietal cells also contribute.
What is the role of CCKBR in gastric acid secretion?
CCKBR is the receptor for gastrin; its blockade or knockdown attenuates gastrin-induced acid secretion, confirming its essential role.
Can somatostatin inhibit gastrin-induced acid secretion?
Yes, somatostatin inhibits gastrin-induced histamine secretion and synthesis in the rat, and somatostatin analogues can reduce pentagastrin-induced acid secretion.
Does ghrelin affect gastric acid secretion?
Ghrelin acts synergistically with gastrin to enhance gastric acid secretion in rats.
What diseases are associated with dysregulated gastrin-induced acid secretion?
Peptic ulcer disease, gastroesophageal reflux disease, gastrinoma (Zollinger-Ellison syndrome), and rebound acid hypersecretion after acid-suppressive therapy.
How can CRISPR be used to study gastrin-induced acid secretion?
CRISPR knockout of CCKBR or GAST can abolish the response, while point mutations and knock-ins can dissect receptor function and track localization.
What models are used to study gastrin-induced acid secretion?
In vivo models include conscious rats with pylorus ligation, CCKBR antagonist treatment, and antisense knockdown; in vitro models include ECL and parietal cell lines.
What is the gastrin-ECL cell-parietal cell axis?
It is the functional circuit where gastrin stimulates ECL cells to release histamine, which then drives parietal cells to secrete acid.
Conclusion
GO:0001698 (gastrin-induced gastric acid secretion) is a fundamental biological process that governs gastric acidity through a coordinated hormonal axis involving gastrin, CCKBR, ECL cells, and parietal cells. Its dysregulation is implicated in prevalent acid-related diseases, and pharmacological modulation of this pathway remains a cornerstone of therapy. The interplay with modulators such as somatostatin, ghrelin, and cholecystokinin adds layers of regulatory complexity. CRISPR-based functional genomics, supported by EDITGENE's services, offers powerful tools to dissect the causal genes and mechanisms underlying this process, paving the way for novel therapeutic strategies.
References
- 1. Lindström E et al.. 2001. Control of gastric acid secretion:the gastrin-ECL cell-parietal cell axis.. Comp Biochem Physiol A Mol Integr Physiol 128(3):505-14 PMID: 11246041
- 2. Ding XQ et al.. 1996. Effect of cholecystokinin-B/gastrin receptor blockade on gastric acid secretion in conscious rats.. Pharmacol Toxicol 79(6):324-30 PMID: 9000260
- 3. Rao RK et al.. 1995. Attenuation of gastrin-induced gastric acid secretion by antisense oligonucleotide to the CCKB/gastrin receptor.. Neuroreport 6(17):2373-7 PMID: 8747156
- 4. Fukumoto K et al.. 2008. Synergistic action of gastrin and ghrelin on gastric acid secretion in rats.. Biochem Biophys Res Commun 374(1):60-3 PMID: 18611393
- 5. Sandvik AK et al.. 1997. Review article: the pharmacological inhibition of gastric acid secretion--tolerance and rebound.. Aliment Pharmacol Ther 11(6):1013-8 PMID: 9663823
- 6. Kondo S et al.. 1993. Somatostatin inhibits gastrin-induced histamine secretion and synthesis in the rat.. Regul Pept 48(3):373-80 PMID: 7506434
- 7. Schmidt WE et al.. 1994. Cholecystokinin is a negative regulator of gastric acid secretion and postprandial release of gastrin in humans.. Gastroenterology 107(6):1610-20 PMID: 7958670
- 8. Gao F et al.. 2006. Effect of somatostatin analogue octreotide injected into the third cerebral ventricle on pentagastrin-induced gastric acid secretion in rats.. World J Gastroenterol 12(17):2767-9 PMID: 16718766
